AstraZeneca PLC (AZN) Q2 2010 Earnings Conference Call July 29, 2010 7:00 AM ET Executives David Brennan – CEO Simon Lowth – CFO Anders Ekblom – EVP, Global Medicines Development Analysts Tim Anderson – Sanford Sachin Jain – Merrill Lynch Gavin Macgregor – Credit Suisse Gbola Amusa – UBS Investment Bank Andrew Baum – Morgan Stanley Marcel Brand – Cheuvreux Lorris Habring (ph) – SEB Seamus Fernandez – Leerink Swann PresentationDavid Brennan
Good afternoon ladies and gentlemen and good morning to those of you in the States who are joining us, I would like to welcome you to our webcast and conference call to go through our second quarter and half year results for 2010. So I am going to start with a review of the key events since we last convened for our full year results back at the end of January and then look at the headline numbers for the first half of the year. Simon Lowth is here, Simon will take you through the second quarter, he will focus on revenue by region and by key brand and also take a detailed walk through the P&L and then will end up with the updated outlook that we have announced around our financial guidance for the full year. Anders Ekblom is also here and he is going to provide the half yearly update on the pipeline and I expect we will have plenty of time for questions. So look forward to that as well. Let me begin with an overview of some of the key developments that have taken place in the past six months and I guess it’s hard not to start anywhere except yesterday’s FDA Advisory Committee Brilinta. Clearly we are pleased that the committee recommended the approval of Brilinta at yesterday’s meeting. So I am sure that the views that have been expressed by the committee and the committee members will help to focus our continuing discussions with the FDA. Obviously, that's now our priority for the U.S. submission.